JP2009515994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515994A5 JP2009515994A5 JP2008541372A JP2008541372A JP2009515994A5 JP 2009515994 A5 JP2009515994 A5 JP 2009515994A5 JP 2008541372 A JP2008541372 A JP 2008541372A JP 2008541372 A JP2008541372 A JP 2008541372A JP 2009515994 A5 JP2009515994 A5 JP 2009515994A5
- Authority
- JP
- Japan
- Prior art keywords
- ratio
- use according
- random copolymer
- composition
- residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 34
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 34
- 229920005604 random copolymer Polymers 0.000 claims 28
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 17
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 17
- 235000019766 L-Lysine Nutrition 0.000 claims 17
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 17
- 239000004472 Lysine Substances 0.000 claims 17
- 229960003767 alanine Drugs 0.000 claims 17
- 229960003646 lysine Drugs 0.000 claims 17
- 229960004441 tyrosine Drugs 0.000 claims 17
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 16
- 125000000539 amino acid group Chemical group 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 13
- 238000006243 chemical reaction Methods 0.000 claims 11
- 230000028993 immune response Effects 0.000 claims 11
- 239000007790 solid phase Substances 0.000 claims 11
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 9
- 229960002989 glutamic acid Drugs 0.000 claims 8
- 238000002560 therapeutic procedure Methods 0.000 claims 8
- 229920001577 copolymer Polymers 0.000 claims 6
- 230000002519 immonomodulatory effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000000781 anti-lymphocytic effect Effects 0.000 claims 2
- 230000001494 anti-thymocyte effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108010074605 gamma-Globulins Proteins 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000037884 allergic airway inflammation Diseases 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000010532 solid phase synthesis reaction Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/283,405 | 2005-11-17 | ||
| US11/283,405 US20060194725A1 (en) | 2004-05-07 | 2005-11-17 | Methods of treating disease with random copolymers |
| PCT/US2006/044699 WO2007078443A2 (en) | 2005-11-17 | 2006-11-17 | Methods of treating unwanted immune response with random copolymers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515994A JP2009515994A (ja) | 2009-04-16 |
| JP2009515994A5 true JP2009515994A5 (https=) | 2009-10-22 |
| JP5676079B2 JP5676079B2 (ja) | 2015-02-25 |
Family
ID=38016876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541372A Expired - Fee Related JP5676079B2 (ja) | 2005-11-17 | 2006-11-17 | ランダムコポリマーによる不要な免疫応答の処置方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060194725A1 (https=) |
| EP (1) | EP1962880A2 (https=) |
| JP (1) | JP5676079B2 (https=) |
| AU (1) | AU2006333437B2 (https=) |
| CA (1) | CA2630364A1 (https=) |
| WO (1) | WO2007078443A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060194725A1 (en) * | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US20090275496A1 (en) * | 2004-05-07 | 2009-11-05 | Peptimmune, Inc. | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
| US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US7589063B2 (en) * | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
| US20070087029A1 (en) * | 2005-10-14 | 2007-04-19 | Pakala Syamasundar V | Localized delivery to the lymphatic system |
| US20080131441A1 (en) * | 2006-09-26 | 2008-06-05 | Manikkam Suthanthiran | Methods of Using FOXP3 Levels to Predict the Outcome of Organs Undergoing Acute Rejection |
| AP3467A (en) | 2007-10-16 | 2015-11-30 | Peptimmune Inc | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| EP2526420A4 (en) * | 2009-11-17 | 2013-09-18 | Ares Trading Sa | METHOD FOR IMPROVING THE STRUCTURE, BIOAVAILABILITY AND EFFICIENCY OF ACCURATE SEQUENCE POLYMER COMPOSITIONS USING SERUM PROTEIN BASED DETECTION OF INCIDENTAL SEQUENCE POLYMER COMPOSITIONS |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| BR112014029417B1 (pt) * | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CA3029654A1 (en) * | 2016-07-01 | 2018-01-04 | Declion Holdings Llc | Amino acid copolymer compositions and uses thereof |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| JP7674263B2 (ja) | 2019-04-17 | 2025-05-09 | テンパス・エーアイ・インコーポレイテッド | コラボレーティブ人工知能の方法およびシステム |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| IL302604A (en) | 2020-11-10 | 2023-07-01 | Palena Therapeutics Inc | Epitope-Encapsulated Random Peptide (EERP) Preparations for the Treatment of Immune-Mediated Conditions and Methods of Use |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US5858964A (en) * | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| US6875451B2 (en) * | 1997-10-15 | 2005-04-05 | Polarx Biopharmaceuticals Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| JP4328050B2 (ja) * | 2000-01-20 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
| EP1188433B1 (en) * | 2000-09-14 | 2007-01-03 | Firmenich Sa | Use of unsaturated esters as perfuming ingredients |
| DE02800437T1 (de) * | 2001-10-03 | 2004-11-11 | The President And Fellows Of Harvard College, Cambridge | Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren |
| US20060194725A1 (en) * | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| JP5495490B2 (ja) * | 2004-05-07 | 2014-05-21 | アレス トレーディング エスエイ | ランダム共重合体を用いる疾患の治療方法 |
-
2005
- 2005-11-17 US US11/283,405 patent/US20060194725A1/en not_active Abandoned
-
2006
- 2006-11-17 WO PCT/US2006/044699 patent/WO2007078443A2/en not_active Ceased
- 2006-11-17 JP JP2008541372A patent/JP5676079B2/ja not_active Expired - Fee Related
- 2006-11-17 EP EP06837923A patent/EP1962880A2/en not_active Ceased
- 2006-11-17 AU AU2006333437A patent/AU2006333437B2/en not_active Ceased
- 2006-11-17 CA CA002630364A patent/CA2630364A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/169,672 patent/US20140249089A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515994A5 (https=) | ||
| TWI361696B (en) | A pharmaceutical composition comprising a human anti-tnf帢 antibody or antigen-binding portion thereof and use of a human anti- tnf帢 antibody or antigen-binding portion thereof | |
| RU2461571C2 (ru) | Белки, связывающие il-12/p40 | |
| JP2014114288A5 (https=) | ||
| CA3080328C (en) | New indications for anti-il-1-beta therapy | |
| JP2006523682A5 (https=) | ||
| JP2021531826A5 (https=) | ||
| US7892563B2 (en) | Methods for treatment of severe acute respiratory syndrome (SARS) | |
| TWI823834B (zh) | 包含亞顆粒或核酸支架之顆粒 | |
| Loleit et al. | Current and future therapies targeting the immune system in multiple sclerosis | |
| KR20150040338A (ko) | 다발경화증 치료용 조합 요법 | |
| JP2021028338A (ja) | テノホビルアラフェナミドの結晶形態 | |
| JP2019509257A5 (https=) | ||
| JP2009521398A5 (https=) | ||
| JP2007530577A5 (https=) | ||
| JP2008540447A5 (https=) | ||
| JP2007512243A5 (https=) | ||
| JP2005538034A5 (https=) | ||
| JP2006519228A5 (ja) | 抗原に対し霊長類を免疫寛容化する抗体の使用法 | |
| JP2015172060A5 (https=) | ||
| JP2024540275A5 (https=) | ||
| JP2006511620A5 (https=) | ||
| JP2006508039A5 (https=) | ||
| JP2022529929A5 (https=) | ||
| RU2006143334A (ru) | Способы лечения заболеваний с помощью статистических сополимеров |